Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 13/20 | 0.63 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.54 |
| ▸ | F10 | P00742 | 2/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.52 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.52 |
| ▸ | EP300 | Q09472 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | F12 | P00748 | 1/20 | 0.49 |
| ▸ | F7 | P08709 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21067443 | 1.00 | F2 (0.63) | F2P2RX7F10PRSS1PRSS2 | |
| SCHEMBL15077016 | 1.00 | F2 (0.63) | F2P2RX7F10PRSS1PRSS2 | |
| SCHEMBL21067304 | 0.90 | F2 (0.61) | F2P2RX7F10PRSS1PRSS2 | |
| SCHEMBL21067308 | 0.90 | F2 (0.61) | F2P2RX7F10PRSS1PRSS2 | |
| SCHEMBL15077020 | 0.90 | F2 (0.61) | F2P2RX7F10PRSS1PRSS2 | |
| SCHEMBL15077017 | 0.89 | F2 (0.69) | F2POLB | |
| SCHEMBL21067749 | 0.89 | F2 (0.69) | F2POLB | |
| SCHEMBL21067746 | 0.89 | F2 (0.69) | F2POLB | |
| SCHEMBL21067851 | 0.87 | F2 (0.67) | F2P2RX7F10PRSS1PRSS2 | |
| SCHEMBL21067854 | 0.87 | F2 (0.67) | F2P2RX7F10PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |